Home  »  Articles   »   Schedule 2, Schedule 3 and Schedule 4 Substances Under the Spotlight

Articles
Schedule 2, Schedule 3 and Schedule 4 Substances Under the Spotlight

November 23, 2020

Department of Health

A health department notice on exclusion of Schedule 2, Schedule 3 and Schedule 4 substances from the operation of certain provisions of the Medicines and Related Substances Act has been amended.

The notice was published in Government Gazette 43294 in May 2020.

The notice excluded Schedule 2, Schedule 3 and Schedule 4 substances from the requirement in section 22A(6)(í) of the act that such substances may be dispensed for no longer than six months.

An amendment to paragraph (a), published in Gazette 43913, stipulates that the intention to continue therapy must be confirmed by the initial prescriber or another authorized prescriber designated to provide care to the patient and such confirmation is documented.

An amendment to paragraph (b) refers to authorized prescribers needing to indicate the number of times the substance may be dispensed (not longer than 12 months).

The amendment also stipulates that the “prescribing and dispensing of prescriptions is done in accordance with the ethical rules, code of conduct and practice guidelines provided by the applicable regulatory body”.

The amendments came into effect on the date of publication and apply for 18 months from 24 April 2020.